Nothing Special   »   [go: up one dir, main page]

WO2006050161A3 - Furopyrimidines et thienopyrimidines therapeutiques - Google Patents

Furopyrimidines et thienopyrimidines therapeutiques Download PDF

Info

Publication number
WO2006050161A3
WO2006050161A3 PCT/US2005/039072 US2005039072W WO2006050161A3 WO 2006050161 A3 WO2006050161 A3 WO 2006050161A3 US 2005039072 W US2005039072 W US 2005039072W WO 2006050161 A3 WO2006050161 A3 WO 2006050161A3
Authority
WO
WIPO (PCT)
Prior art keywords
furopyrimidines
thienopyrimidines
therapeutic
compounds
iii
Prior art date
Application number
PCT/US2005/039072
Other languages
English (en)
Other versions
WO2006050161A2 (fr
Inventor
Yarlagadda S Babu
Pooran Chand
Minwan Wu
Pravin L Kotian
V Satish Kumar
Tsu-Hsing Lin
Yahya El-Kattan
Ajit K Ghosh
Original Assignee
Biocryst Pharm Inc
Yarlagadda S Babu
Pooran Chand
Minwan Wu
Pravin L Kotian
V Satish Kumar
Tsu-Hsing Lin
Yahya El-Kattan
Ajit K Ghosh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc, Yarlagadda S Babu, Pooran Chand, Minwan Wu, Pravin L Kotian, V Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K Ghosh filed Critical Biocryst Pharm Inc
Priority to CNA2005800448820A priority Critical patent/CN101166750A/zh
Priority to JP2007539198A priority patent/JP5089395B2/ja
Priority to AU2005302448A priority patent/AU2005302448B2/en
Priority to EP05820258A priority patent/EP1814561A4/fr
Priority to US11/666,264 priority patent/US8133870B2/en
Priority to NZ555441A priority patent/NZ555441A/en
Priority to CA002585079A priority patent/CA2585079A1/fr
Priority to US11/332,858 priority patent/US7429571B2/en
Priority to AU2006230023A priority patent/AU2006230023A1/en
Priority to PCT/US2006/010948 priority patent/WO2006104945A2/fr
Priority to US11/388,060 priority patent/US7514410B2/en
Priority to JP2008504203A priority patent/JP5107228B2/ja
Priority to CA002602533A priority patent/CA2602533A1/fr
Priority to EP12171343A priority patent/EP2537520A1/fr
Priority to EP06739630A priority patent/EP1863500A2/fr
Publication of WO2006050161A2 publication Critical patent/WO2006050161A2/fr
Priority to IL182498A priority patent/IL182498A0/en
Publication of WO2006050161A3 publication Critical patent/WO2006050161A3/fr
Priority to US12/399,521 priority patent/US8163703B2/en
Priority to US13/372,067 priority patent/US20120213735A1/en
Priority to US13/430,341 priority patent/US20130078218A1/en
Priority to JP2012128869A priority patent/JP2012229216A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formules I, II, et III, ainsi que des compositions pharmaceutiques comprenant ces composés, et des procédés et des intermédiaires de synthèse qui permettent de préparer ces composés. On utilise les composés des formules I, II, et III comme agents antiviraux et/ou agents anticancéreux.
PCT/US2005/039072 2004-10-29 2005-10-28 Furopyrimidines et thienopyrimidines therapeutiques WO2006050161A2 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CNA2005800448820A CN101166750A (zh) 2004-10-29 2005-10-28 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
JP2007539198A JP5089395B2 (ja) 2004-10-29 2005-10-28 治療用フロピリミジンおよびチエノピリミジン
AU2005302448A AU2005302448B2 (en) 2004-10-29 2005-10-28 Therapeutic furopyrimidines and thienopyrimidines
EP05820258A EP1814561A4 (fr) 2004-10-29 2005-10-28 Furopyrimidines et thienopyrimidines therapeutiques
US11/666,264 US8133870B2 (en) 2004-10-29 2005-10-28 Therapeutic furopyrimidines and thienopyrimidines
NZ555441A NZ555441A (en) 2004-10-29 2005-10-28 Therapeutic furopyrimidines and thienopyrimidines
CA002585079A CA2585079A1 (fr) 2004-10-29 2005-10-28 Furopyrimidines et thienopyrimidines therapeutiques
US11/332,858 US7429571B2 (en) 2004-10-29 2006-01-16 Therapeutic furopyrimidines and thienopyrimidines
EP06739630A EP1863500A2 (fr) 2005-03-29 2006-03-23 Therapies contre l'hepatite c
AU2006230023A AU2006230023A1 (en) 2005-03-29 2006-03-23 Hepatitis C therapies
PCT/US2006/010948 WO2006104945A2 (fr) 2005-03-29 2006-03-23 Therapies contre l'hepatite c
US11/388,060 US7514410B2 (en) 2005-03-29 2006-03-23 Hepatitis C therapies
JP2008504203A JP5107228B2 (ja) 2005-03-29 2006-03-23 Ｃ型肝炎治療
CA002602533A CA2602533A1 (fr) 2005-03-29 2006-03-23 Therapies contre l'hepatite c
EP12171343A EP2537520A1 (fr) 2005-03-29 2006-03-23 Thérapies hépatiques C
IL182498A IL182498A0 (en) 2004-10-29 2007-04-12 Therapeutic furopyrimidines and thienopyrimidines
US12/399,521 US8163703B2 (en) 2005-03-29 2009-03-06 Hepatitis C therapies
US13/372,067 US20120213735A1 (en) 2004-10-29 2012-02-13 Therapeutic furopyrimidines and thienopyrimidines
US13/430,341 US20130078218A1 (en) 2005-03-29 2012-03-26 Hepatitis c therapies
JP2012128869A JP2012229216A (ja) 2005-03-29 2012-06-06 Ｃ型肝炎治療

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US62306504P 2004-10-29 2004-10-29
US60/623,065 2004-10-29
US64175405P 2005-01-07 2005-01-07
US60/641,754 2005-01-07
US66583205P 2005-03-29 2005-03-29
US60/665,832 2005-03-29
US69257205P 2005-06-22 2005-06-22
US60/692,572 2005-06-22
US72821505P 2005-10-19 2005-10-19
US60/728,215 2005-10-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/332,858 Continuation US7429571B2 (en) 2004-10-29 2006-01-16 Therapeutic furopyrimidines and thienopyrimidines

Publications (2)

Publication Number Publication Date
WO2006050161A2 WO2006050161A2 (fr) 2006-05-11
WO2006050161A3 true WO2006050161A3 (fr) 2007-12-21

Family

ID=36319689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039072 WO2006050161A2 (fr) 2004-10-29 2005-10-28 Furopyrimidines et thienopyrimidines therapeutiques

Country Status (10)

Country Link
US (3) US8133870B2 (fr)
EP (1) EP1814561A4 (fr)
JP (2) JP5089395B2 (fr)
KR (1) KR20070100237A (fr)
CN (1) CN101166750A (fr)
AU (1) AU2005302448B2 (fr)
CA (1) CA2585079A1 (fr)
IL (1) IL182498A0 (fr)
NZ (1) NZ555441A (fr)
WO (1) WO2006050161A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568379A1 (fr) 2004-06-15 2005-12-29 Merck & Co., Inc. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
US7696182B2 (en) 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
EP1863500A2 (fr) * 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Therapies contre l'hepatite c
US8344132B2 (en) 2005-06-22 2013-01-01 BioCryst Pharmaceticals, Inc. Methods for the preparation of 9-deazapurine derivatives
BRPI0614863A2 (pt) * 2005-08-15 2011-04-19 Hoffmann La Roche uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
WO2008045535A2 (fr) * 2006-10-12 2008-04-17 Research Foundation Of The City University Of New York Dérivé de nucléoside convertible
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
GB2471806B (en) * 2008-04-03 2012-12-19 Spring Bank Pharmaceuticals Inc Compositions and methods for treating viral infections
EA019883B1 (ru) 2008-04-23 2014-07-30 Джилид Сайэнс, Инк. Карбануклеозидные аналоги для противовирусной терапии
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8946239B2 (en) * 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2010011748A2 (fr) * 2008-07-22 2010-01-28 Biocryst Pharmaceuticals, Inc. Intermédiaires et procédés de synthèse
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
PT2396340E (pt) * 2009-02-10 2014-03-26 Gilead Sciences Inc Análogos de carba-nucleosídeo para tratamento antiviral
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
CA2783475A1 (fr) 2009-12-23 2011-06-30 Biocryst Pharmaceuticals, Inc. Composes heterocycliques comme inhibiteurs de la janus kinase
CN104017020B (zh) * 2010-03-31 2017-04-12 吉利德制药有限责任公司 核苷氨基磷酸酯
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
WO2013039920A1 (fr) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales
AR090699A1 (es) 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
MX2015005949A (es) * 2012-11-16 2015-09-08 Biocryst Pharm Inc Nucleosidos que contienen aza-azucar antiviral.
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
HRP20220740T1 (hr) 2015-09-16 2022-11-11 Gilead Sciences, Inc. Postupci za liječenje virusnih infekcija arenaviridae
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR20220146668A (ko) 2016-09-07 2022-11-01 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
KR102592899B1 (ko) 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
AU2018235754B2 (en) 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
EP4219513A1 (fr) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Forme cristalline de (s)-2-éthylbutyl 2-((s)-((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f! [1,2,4 triazin-7-yl)-5-cyano-3,4-dihydroxy tétrahydrofuranne 2-yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate
CA3077489A1 (fr) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprenant un inhibiteur d'arn polymerase et de la cyclodextrine pour le traitement d'infections virales
WO2019200005A1 (fr) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Traitement de patients infectés par le virus de l'hépatite c avec une cirrhose
TW202313067A (zh) 2020-01-27 2023-04-01 美商基利科學股份有限公司 治療sars cov-2感染之方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
CA3172483A1 (fr) 2020-04-06 2021-10-14 Scott Ellis Formulations d'inhalation d'analogues de carbanucleosides a substitution 1'-cyano
KR20230018473A (ko) 2020-05-29 2023-02-07 길리애드 사이언시즈, 인코포레이티드 렘데시비르 치료 방법
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
FI4204421T3 (fi) 2020-08-27 2024-06-25 Gilead Sciences Inc Koostumuksia ja menetelmiä virusinfektioiden hoitoon
JPWO2023022216A1 (fr) 2021-08-20 2023-02-23
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093290A2 (fr) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
WO2004058792A1 (fr) * 2002-12-23 2004-07-15 Idenix (Cayman) Limited Procede de production de promedicaments a base de 3'-nucleosides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
EP0071227B1 (fr) * 1981-07-31 1987-11-11 Sloan-Kettering Institute For Cancer Research Bêta-glycosyl C-nucléosides à activité anti-leucémique
ES2167710T3 (es) 1996-02-07 2002-05-16 Janssen Pharmaceutica Nv Tiofenopirimidinas.
EA002769B1 (ru) 1996-08-28 2002-08-29 Пфайзер Инк. Замещенные 6,5-гетеробициклические производные
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
WO1998049899A1 (fr) 1997-05-08 1998-11-12 Agrevo Uk Limited Fongicides
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
RS50236B (sr) 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
WO2003051899A1 (fr) * 2001-12-17 2003-06-26 Ribapharm Inc. Banques de deazapurine nucleosides et composes
CA2568379A1 (fr) 2004-06-15 2005-12-29 Merck & Co., Inc. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
EP1863500A2 (fr) 2005-03-29 2007-12-12 Biocryst Pharmaceuticals, Inc. Therapies contre l'hepatite c

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093290A2 (fr) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
WO2004058792A1 (fr) * 2002-12-23 2004-07-15 Idenix (Cayman) Limited Procede de production de promedicaments a base de 3'-nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIRGIS ET AL.: "Direct C-glycosylation of guanine analogues: the synthesis and antiviral activity of certain 7- and 9-deazaguanine C-nucleosides", J. MED. CHEM., vol. 33, 1990, pages 2750 - 2755, XP008122479 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections

Also Published As

Publication number Publication date
CN101166750A (zh) 2008-04-23
US20120213735A1 (en) 2012-08-23
JP5089395B2 (ja) 2012-12-05
US7429571B2 (en) 2008-09-30
US20080300200A1 (en) 2008-12-04
US8133870B2 (en) 2012-03-13
US20060165655A1 (en) 2006-07-27
CA2585079A1 (fr) 2006-05-11
EP1814561A4 (fr) 2012-12-19
WO2006050161A2 (fr) 2006-05-11
AU2005302448A1 (en) 2006-05-11
IL182498A0 (en) 2007-09-20
JP2008518934A (ja) 2008-06-05
EP1814561A2 (fr) 2007-08-08
KR20070100237A (ko) 2007-10-10
AU2005302448B2 (en) 2012-07-19
JP2012167126A (ja) 2012-09-06
NZ555441A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
WO2006050161A3 (fr) Furopyrimidines et thienopyrimidines therapeutiques
WO2009111653A3 (fr) Agents thérapeutiques antiviraux
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2008089105A3 (fr) Analogues de nucléosides antiviraux
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
WO2009005690A3 (fr) Composés antiviraux
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2006020276A3 (fr) Composés antiviraux
WO2009005677A3 (fr) Composés antiviraux
WO2009005676A3 (fr) Composés antiviraux
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2010036407A3 (fr) Analogues nucléosidiques antiviraux
ZA200704001B (en) Potentiators of glutamate receptors
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
WO2008083248A3 (fr) Analogues de cyclopamine
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2004092135A3 (fr) Composes therapeutiques
WO2007066337A3 (fr) Derives chimiques ameliores de jasmonate, compositions pharmaceutiques et procedes d'utilisation correspondants
WO2007066336A3 (fr) Derives chimiques de jasmonate, compositions pharmaceutiques et procedes d’utilisation correspondants
WO2006133006A3 (fr) 1-methyl-1h-pyrazole-4-carboxamides utiles comme agents chimiotherapeutiques anticancereux
WO2004110990A3 (fr) Inhibiteurs de p38 et leurs methodes d'utilisation
WO2005103010A3 (fr) Composes chimiques
WO2008098077A3 (fr) Composés thérapeutiques
WO2009059047A3 (fr) Composés tricycliques et procédés d'utilisation desdits composés

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580044882.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11332858

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 11332858

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12007500773

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 182498

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2585079

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007539198

Country of ref document: JP

Ref document number: 1020077009688

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1720/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005302448

Country of ref document: AU

Ref document number: 555441

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005820258

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005302448

Country of ref document: AU

Date of ref document: 20051028

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005302448

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005820258

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11666264

Country of ref document: US